WEEKLY e-ALERT  [ PREMIUM EDITION ]
Pharma China (www.pharmachinaonline.com) is the most influential English media and source of business intelligence covering the Chinese pharmaceutical sector. Pharma China caters for the growing needs of the international pharmaceutical industry for up-to-date and insightful information and intelligence on China’s burgeoning but increasingly complex healthcare marketplace, and is subscribed by most MNC pharma companies, leading CROs, investment banks, consulting firms active in China as well as relevant industry associations and government agencies.

Note: To view full text of free articles, you need to register as a basic member first and then log in. To view premium articles, you need to subscribe to Pharma China as a premium member. For more information or subscription, please contact info@pharmachinaonline.com. If you wish to unsubscribe from this e-Alert, please reply this e-mail with "Remove" in the subject line.
Case Studies
GNC: China Strategy Hits Tariff Shoals(5/23/2019 )  (Premium)
  The gathering clouds in the trade relationship between China and the U.S. - and the ever-present threat of tariffs on GNC's products - are driving a portion of the declines in share price seen over the last couple months. The long focus on the China business only aggravates the apparent impact.
Editor´s Picks
China: Survival of the Fittest or Cheapest?(5/22/2019 )  (Premium)
  The past year is set to be a milestone year for China's pharmaceutical regulatory reform as the newly formed NMPA continues to aggressively cut back on red tape for new drug approvals, this Hogan Lovells article suggests.
Is China The New Frontier For Indian Generics?(5/22/2019 )  (free)
  China, the world¡¯s second-largest pharma market, is expected to be the next growth driver for Indian drugmakers amid a slowdown in the U.S.
Jack Ma Is Selling Cancer Coverage for Pennies a Month in China(5/21/2019 )  (Premium)
  This Bloomberg article reports on China's emerging crowdfunding sector for health care ¨C- an emerging industry in China that itself is becoming crowded. Ant Financial is one of at least 50 companies, including a startup backed by Tencent Holdings Ltd., upending the conventional health-insurance business by creating what essentially are online collectives..
Diabetes Crisis Draws Challengers for $22 Billion Insulin Market(5/21/2019 )  (Premium)
  This Bloomberg article by Bruce Einhorn summarizes some emerging trends with the U.S. diabetes market, including 1) Sanofi and Mylan team up with Asian partners on biosimilars; and 2) China and India-made insulin could slash prices for patients.
FDA Defends Oversight Amid Questions of Safety of Generic Drugs Made in India and China(5/21/2019 )  (Premium)
  This USAToday article quoted the U.S. FDA as saying that "we found a lot of bad things" - The FDA¡¯s report released this week includes average ¡°site inspection scores¡± over the past decade at drug factories worldwide. Factories in Europe had the highest average drug quality score of 7.9 on a 10-point rating scale, followed by U.S. factories at 7.7.
Trade War With China Threatens To Make Problems With Generic Medicine Worse(5/21/2019 )  (Premium)
  This Forbes article by Judy Stone concludes that "with a trade war with China, we put our antibiotic supply at risk. We need new manufacturing capabilities on the mainland as well as a more rigorous FDA inspections process."
The Market
NH Reports 2018 Data on the Chinese OTC Analgesics Markets(5/22/2019 )  (Premium)
  According to the latest data from Nicholas Hall, the Chinese OTC analgesics market rose 7% (by local currency) to CNY 20.9 blon ($3,102.4 mln) in full year 2018 on the basis of an exchange rate at US$1.00 = CNY 6.73.
Industry News
Joinn Labs to Buy Clinical CRO Biomere for $27.3M(5/23/2019 )  (Premium)
  China's Joinn Laboratories will acquire the clinic trial contract business of Biomere, formerly known as Biomedical Research Models, for US$27.3 million to form synergies with its existing business and expand the influence of its Joinn brand in the US, the Chinese provider of clinical trial services to pharmaceutical giants said in a statement.
WuXi STA and Dizal Pharma Sign CMC Development and Manufacturing Agreement(5/21/2019 )  (Premium)
  Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
WuXi Biologics Signed Letter of Intent for Long-Term Vaccine Manufacturing Contract(5/21/2019 )  (Premium)
  WuXi Biologics announced on May 21 that it has entered into a strategic partnership Letter of Intent (LOI) with a global vaccine leader, pursuant to which WuXi Vaccines will build a dedicated facility and supply a commercial product for the global market.
Sandoz's Generic Rosuvastatin Cleared in China(5/21/2019 )  (Premium)
  The NMPA has approved Sandoz's generic version of AstraZeneca's high cholesterol med Crestor (rosuvastatin calcium). Sandoz is the first MNC to receive such an approval under the recently introduced Generic Quality Consistency Evaluation (GQCE) system.
Mabpharm Announces Proposed Listing on Hong Kong Stock Exchange(5/21/2019 )  (Premium)
  Mabpharm Ltd. has announced that the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong. Mabpharm will open IPO in Hong Kong at 9 a.m., May 20, 2019 and close at 12:00 noon, May 24, 2019.
China Raises Tariffs on U.S. MedPharm Products to 25% as Part of Its Retaliatory Action(5/20/2019 )  (Premium)
  Many of the products affected by the Chinese tariff hike fall into the MedPharm category and they include both common medicines such as insulin and ibuprofen, as well as medical device products including large machines such as B type ultrasonic diagnostic devices and color ultrasonic devices.
General Health
Premier Li Urges More Efforts to Advance Healthcare Reforms(5/20/2019 )  (Premium)
  Premier Li Keqiang has urged intensified efforts and more effective measures to advance the country's healthcare reforms.Li made the remarks in a written instruction to a video and telephone conference on medical reforms held in Beijing on May 17.
Legal/IPR News
European Chamber Report Calls for Urgent China Reforms amid Increasing Global Challenges(5/21/2019 )  (Premium)
  The EU Chamber of Commerce in China, in cooperation with Roland Berger, released on May 20 its European Business in China Business Confidence Survey 2019. The report raises significant concerns, with issues like the Chinese economic slowdown and the US-China Trade War posing increasingly difficult challenges.
People in the News
Senior Chinese PharmChem Executive Arrested for Shipping 500 kilos of Drugs to the U.S.(5/23/2019 )  (Premium)
  A Chinese man who worked as a high-level executive at chemical and pharmaceutical companies in China was arrested and accused of participating in a scheme that brought 500 kilos of drugs to the United States, including chemicals similar to the deadly opioid fentanyl.
© Wicon International Group¡¡Support by: www.heightow.com Home | Site map | Contact Us | Links